Trial · NCT03579875
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT03579875, Phase 2, Recruiting, Masonic Cancer Center, University of Minnesota
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders. Trials, record NCT03579875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03579875
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
- NCT number
- NCT03579875
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
- Interventions
Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, Alemtuzumab, Melphalan, Rituximab
- First posted
- 2018-07-09
- Last updated
- 2026-01-30
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Grade II-IV acute graft versus host disease (GVHD) | Day 100 | incidence of grade II-IV acute graft versus host disease (GVHD) |
| Secondary | Neutrophil engraftment | Day 42 | Rate of neutrophil engraftment (defined as the first of three consecutive days after HCT that the patient's absolute neutrophil counts is ≥ 0.5x109 per liter) |
| Secondary | Platelet engraftment | Day 42 | Time to platelet engraftment (First of three consecutive days after HCT that the patient's platelet count ≥ 20x10\^9 per liter) |
| Secondary | Acute graft versus host disease (aGVHD) | Day 100 | Incidence of grade III-IV acute graft versus host disease |
| Secondary | Chronic graft versus host disease (cGVHD) | 1 Year after transplant | Incidence of chronic graft versus host disease after transplant |
| Secondary | Regimen related toxicity | 30 Days after transplant | Incidence of regimen related toxicity based on CTCAE v5 |
| Secondary | Bacterial, viral and fungal infections | 1 Year after transplant | Incidence of bacterial, viral and fungal infections |
| Secondary | Opportunistic infections | 100 Days after transplant | Incidence of opportunistic infections |
| Secondary | Overall survival (OS) | 1 Year after transplant | Incidence of overall survival |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03579875
GET https://conductscience.org/api/trials/v1/NCT03579875/registered